Inhibitory action of clozapine on rat ventral tegmental area dopamine neurons following increased levels of endogenous kynurenic acid

Neuropsychopharmacology

Volumn 28, Issue 10, 2003, Pages 1770-1777

  Schwieler, Lilly ^a   Erhardt, Sophie ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

Author keywords

Bursts; Electrophysiology; Haloperidol; NMDA; PNU 156561A; Schizophrenia

Indexed keywords

CLOZAPINE; DOPAMINE; HALOPERIDOL; KYNURENIC ACID; NICOTINIC RECEPTOR BLOCKING AGENT; PIPERAZINE DERIVATIVE; PNU 156561 A; UNCLASSIFIED DRUG; 4 AMINOBUTYRIC ACID RECEPTOR BLOCKING AGENT; BUTYRIC ACID DERIVATIVE; DOPAMINE RECEPTOR BLOCKING AGENT; FCE 28833;

ANIMAL EXPERIMENT; ARTICLE; BRAIN ELECTROPHYSIOLOGY; CONTROLLED STUDY; DOPAMINERGIC ACTIVITY; DOPAMINERGIC NERVE CELL; DOPAMINERGIC TRANSMISSION; DRUG EFFECT; DRUG INDUCED DISEASE; DRUG INHIBITION; FACILITATION; HYPERDOPAMINERGIA; NEGATIVE SYNDROME; NERVE CELL EXCITABILITY; NONHUMAN; PREPULSE INHIBITION; PRIORITY JOURNAL; RAT; SCHIZOPHRENIA; VENTRAL TEGMENTUM; ACTION POTENTIAL; ANIMAL; CYTOLOGY; DOSE RESPONSE; DRUG ANTAGONISM; DRUG INTERACTION; MALE; METABOLISM; NERVE CELL; NERVE CELL INHIBITION; NONPARAMETRIC TEST; PHYSIOLOGY; SPRAGUE DAWLEY RAT;

ACTION POTENTIALS; ANIMALS; BUTYRATES; CLOZAPINE; DOPAMINE; DOPAMINE ANTAGONISTS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG INTERACTIONS; GABA ANTAGONISTS; HALOPERIDOL; KYNURENIC ACID; MALE; NEURAL INHIBITION; NEURONS; RATS; RATS, SPRAGUE-DAWLEY; STATISTICS, NONPARAMETRIC; VENTRAL TEGMENTAL AREA;

EID: 0642308239     PISSN: 0893133X     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.npp.1300255     Document Type: Article

References (63)

1. Abi-Dargham A, Rodenhiser J, Printz D, Zea-Ponce Y, Gil R, Kegeles LS et al (2000). From the cover: increased baseline occupancy of D2 receptors by dopamine in schizophrenia. Proc Natl Acad Sci USA 97: 8104-8109.
2. Andén NE, Stock G (1973). Effect of clozapine on the turnover of dopamine in the corpus striatum and in the limbic system. J Pharm Pharmacol 25: 346-348.
3. Arvanov VL, Liang X, Schwartz J, Grossman S, Wang RY (1997). Clozapine and haloperidol modulate N-methyl-D-aspartate- and non-N-methyl-D-aspartate receptor-mediated neurotransmission in rat prefrontal cortical neurons in vitro. J Pharmacol Exp Ther 283: 226-234.
4. Bartholini G (1976). Differential effect of neuroleptic drugs on dopamine turnover in the extrapyramidal and limbic system. J Pharm Pharmacol 28: 429-433.
5. Birch PJ, Grossman CJ, Hayes AG (1988). Kynurenic acid antagonises responses to NMDA via an action at the strychnine-insensitive glycine receptor. Eur J Pharmacol 154: 85-87.
6. Brunello N, Masotto C, Steardo L, Markstein R, Racagni G (1995). New insights into the biology of schizophrenia through the mechanism of action of clozapine. Neuropsychopharmacology 13: 177-213.
7. Canton H, Verriele L, Colpaert FC (1990). Binding of typical and atypical antipsychotics to 5-HT1C and 5-HT2 sites: clozapine potently interacts with 5-HT1C sites. Eur J Pharmacol 191: 93-96.
8. Carlsson A, Waters N, Holm-Waters S, Tedroff J, Nilsson M, Carlsson ML (2001). Interactions between monoamines, glutamate, and GABA in schizophrenia: new evidence. Annu Rev Pharmacol Toxicol 41: 237-260.
9. Carr DB, Sesack SR (2000). GABA-containing neurons in the rat ventral tegmental area project to the prefrontal cortex. Synapse 38: 114-123.
10. Chiodo LA, Bunney BS (1983). Typical and atypical neuroleptics: differential effects of chronic administration on the activity of A9 and A10 midbrain dopaminergic neurons. J Neurosci 3: 1607-1619.
11. Chiodo LA, Bunney BS (1985). Possible mechanisms by which repeated clozapine administration differentially affects the activity of two subpopulations of midbrain dopamine neurons. J Neurosci 5: 2539-2544.
12. Claghorn J, Honigfeld G, Abuzzahab Sr FS, Wang R, Steinbook R, Tuason V et al (1987). The risks and benefits of clozapine versus chlorpromazine. J Clin Psychopharmacol 7: 377-384.
13. Coward DM (1992). General pharmacology of clozapine. Br J Psychiatry Suppl (17): 5-11.
14. Coward DM, Imperato A, Urwyler S, White TG (1989). Biochemical and behavioural properties of clozapine. Psychopharmacology 99(Suppl): S6-S12.
15. Deutch AY, Moghaddam B, Innis RB, Krystal JH, Aghajanian GK, Bunney BS et al (1991). Mechanisms of action of atypical antipsychotic drugs. Implications for novel therapeutic strategies for schizophrenia. Schizophr Res 4: 121-156.
16. Erhardt S, Blennow K, Nordin C, Skogh E, Lindström LH, Engberg G (2001c). Elevated endogenous kynurenic acid in schizophrenia. Neurosci Lett 313: 96-98.
17. Erhardt S, Engberg G (2000). Excitation of nigral dopamine neurons by the GABA-A-receptor agonist muscimol is mediated via a release of glutamate. Life Sci 67: 1901-1911.
18. Erhardt S, Engberg G (2002). Increased phasic activity of dopaminergic neurones in the rat ventral tegmental area following pharmacologically elevated levels of endogenous kynurenic acid. Acta Physiol Scand 175: 45-53.
19. Erhardt S, Hajos M, Lindberg A, Engberg G (2000). Nicotine induced excitation of locus coeruleus neurons is blocked by elevated levels of endogenous kynurenic acid. Synapse 37: 104-108.
20. Erhardt S, Mathé JM, Chergui K, Engberg G, Svensson TH (2002b). GABAB-receptors modulate the firing pattern of dopamine neurons in the ventral tegmental area. Naunyn-Schmiedeberg's Arch Pharmacol 365: 173-180.
21. Erhardt S, Öberg H, Engberg G (2001b). Pharmacologically elevated levels of endogenous kynurenic acid prevent nicotine-induced activation of nigral dopamine neurons. Naunyn-Schmiedeberg's Arch Pharmacol 363: 21-27.
22. Erhardt S, Öberg H, Mathé JM, Engberg G (2001a). Pharmacological elevation of endogenous kynurenic acid levels activates nigral dopamine neurons. Amino Acids 20: 353-362.
23. Erhardt S, Schwieler L, Engberg G (2002a). Excitatory and inhibitory responses of dopamine neurons in the ventral tegmental area to nicotine. Synapse 43: 227-237.
24. Evins AE, Amico E, Posever TA, Toker R, Goff DC (2002). D-Cycloserine added to risperidone in patients with primary negative symptoms of schizophrenia. Schizophr Res 56: 19-23.
25. Farde L, Nordstrom AL, Wiesel FA, Pauli S, Halldin C, Sedvall G (1992). Positron emission tomographic analysis of central D1 and D2 dopamine receptor occupancy in patients treated with classical neuroleptics and clozapine. Relation to extrapyramidal side effects. Arch Gen Psychiatry 49: 538-544.
26. French ED (1994). Phencyclidine and the midbrain dopamine system: electrophysiology and behavior. Neurotoxicol Teratol 16: 355-362.
27. French ED, Mura A, Wang T (1993). MK-801, phencyclidine (PCP), and PCP-like drugs increase burst firing in rat A10 dopamine neurons: comparison to competitive NMDA antagonists. Synapse 13: 108-116.
28. Ganong AH, Cotman CW (1986). Kynurenic acid and quinolinic acid act at N-methyl-D-aspartate receptors in the rat hippocampus. J Pharmacol Exp Ther 236: 293-299.
29. Gerlach J (2002). Improving outcome in schizophrenia: the potential importance of EPS and neuroleptic dysphoria. Ann Clin Psychiatry 14: 47-57.
30. Gessa GL, Devoto P, Diana M, Flore G, Melis M, Pistis M (2000). Dissociation of haloperidol, clozapine, and olanzapine effects on electrical activity of mesocortical dopamine neurons and dopamine release in the prefrontal cortex. Neuropsychopharmacology 22: 642-649.
31. Goff DC, Tsai G, Levitt J, Amico E, Manoach D, Schoenfeld DA et al (1999). A placebo-controlled trial of D-cycloserine added to conventional neuroleptics in patients with schizophrenia. Arch Gen Psychiatry 56: 21-27.
32. Grace AA, Bunney BS (1984a). The control of firing pattern in nigral dopamine neurons: single spike firing. J Neurosci 4: 2866-2876.
33. Grace AA, Bunney BS (1984b). The control of firing pattern in nigral dopamine neurons: burst firing. J Neurosci 4: 2877-2890.
34. Heresco-Levy U, Javitt DC, Ermilov M, Mordel C, Silipo G, Lichtenstein M (1999). Efficacy of high-dose glycine in the treatment of enduring negative symptoms of schizophrenia. Arch Gen Psychiatry 56: 29-36.
35. Heresco-Levy U, Javitt DC, Ermilov M, Silipo G, Shimoni J (1998). Double-blind, placebo-controlled, crossover trial of D-cycloserine adjuvant therapy for treatment-resistant schizophrenia. Int J Neuropsychopharmacol 1: 131-135.
36. Hilmas C, Pereira EF, Alkondon M, Rassoulpour A, Schwarcz R, Albuquerque EX (2001). The brain metabolite kynurenic acid inhibits alpha7 nicotinic receptor activity and increases non-alpha7 nicotinic receptor expression: physiopathological implications. J Neurosci 21: 7463-7473.
37. Ichikawa J, Dai J, Meltzer HY (2002). 5-HT(1A) and 5-HT(2A) receptors minimally contribute to clozapine-induced acetylcholine release in rat medial prefrontal cortex. Brain Res 939: 34-42.
38. Ichikawa J, Ishii H, Bonaccorso S, Fowler WL, O'Laughlin IA, Meltzer HY (2001). 5-HT(2A) and D(2) receptor blockade increases cortical DA release via 5-HT(1A) receptor activation: a possible mechanism of atypical antipsychotic-induced cortical dopamine release. J Neurochem 76: 1521-1531.
39. Javitt DC, Zylberman I, Zukin SR, Heresco-Levy U, Lindenmayer JP (1994). Amelioration of negative symptoms in schizophrenia by glycine. Am J Psychiatry 151: 1234-1236.
40. Kalivas PW, Churchill L, Klitenick MA (1993). GABA and enkephalin projection from the nucleus accumbens and ventral pallidum to the ventral tegmental area. Neuroscience 57: 1047-1060.
41. Kessler M, Terramani T, Lynch G, Baudry M (1989). A glycine site associated with N-methyl-D-aspartic acid receptors: characterization and identification of a new class of antagonists. J Neurochem 52: 1319-1328.
42. McGehee DS, Heath MJ, Gelber S, Devay P, Role LW (1995). Nicotine enhancement of fast excitatory synaptic transmission in CNS by presynaptic receptors. Science 269: 1692-1696.
43. Meltzer HY, Nash JF (1991). Effects of antipsychotic drugs on serotonin receptors. Pharmacol Rev 43: 587-604.
44. Moghaddam B, Bunney BS (1990). Acute effects of typical and atypical antipsychotic drugs on the release of dopamine from prefrontal cortex, nucleus accumbens, and striatum of the rat: an in vivo microdialysis study. J Neurochem 54: 1755-1760.
45. Murase S, Mathé JM, Grenhoff J, Svensson TH (1993). Effects of dizocilpine (MK-801) on rat midbrain dopamine cell activity: differential actions of firing pattern related to anatomical localization. J Neural Transm 91: 13-25.
46. Ossowska K, Pietraszek M, Wardas J, Nowak G, Wolfarth S (1999). Chronic haloperidol and clozapine administration increases the number of cortical NMDA receptors in rats. Naunyn Schmiedeberg's Arch Pharmacol 359: 280-287.
47. Parsons CG, Danysz W, Quack G, Hartmann S, Lorenz B, Wollenburg C et al (1997). Novel systemically active antagonists of the glycine site of the N-methyl-D-aspartate receptor: electrophysiological, biochemical and behavioral characterization. J Pharmacol Exp Ther 283: 1264-1275.
48. Paxinos G, Watson C (1998). The Rat Brain in Stereotaxic Coordinates, 4th edn Academic Press: New York.
49. Phillipson OT (1979). Afferent projections to the ventral tegmental area of Tsai and interfascicular nucleus: a horse-radish peroxidase study in the rat. J Comp Neurol 187: 117-144.
50. Pucak ML, Grace AA (1994). Evidence that systemically administered dopamine antagonists activate dopamine neuron firing primarily by blockade of somatodendritic autoreceptors. J Pharmacol Exp Ther 271: 1181-1192.
51. Pucak ML, Grace AA (1996). Effects of haloperidol on the activity and membrane physiology of substantia nigra dopamine neurons recorded in vitro. Brain Res 713: 44-52.
52. Schwarcz R, Rassoulpour A, Wu HQ, Medoff D, Tamminga CA, Roberts RC (2001). Increased cortical kynurenate content in schizophrenia. Biol Psychiatry 50: 521-530.
53. Sesack SR, Deutch AY, Roth RH, Bunney BS (1989). Topographical organization of the efferent projections of the medial prefrontal cortex in the rat: an anterograde tract-tracing study with Phaseolus vulgaris leucoagglutinin. J Comp Neurol 290: 213-242.
54. Snyder SH, Greenberg D, Yamumura HI (1974). Antischizophrenic drugs: affinity for muscarinic cholinergic receptor sites in the brain predicts extrapyramidal effects. J Psychiatr Res 11: 91-95.
55. Speciale C, Wu HQ, Cini M, Marconi M, Varasi M, Schwarcz R (1996). (R,S)-3,4-dichlorobenzoylalanine (FCE 28833A) causes a large and persistent increase in brain kynurenic acid levels in rats. Eur J Pharmacol 315: 263-267.
56. Squires RF, Saederup E (1998). Clozapine and several other antipsychotic/antidepressant drugs preferentially block the same 'core' fraction of GABA(A) receptors. Neurochem Res 23: 1283-1290.
57. Tsai G, Yang P, Chung LC, Lange N, Coyle JT (1998). D-serine added to antipsychotics for the treatment of schizophrenia. Biol Psychiatry 44: 1081-1089.
58. Tung CS, Grenhoff J, Svensson TH (1991). Kynurenate blocks the acute effects of haloperidol on midbrain dopamine neurons recorded in vivo. J Neural Transm Gen Sect 84: 53-64.
59. Van Tol HH, Bunzow JR, Guan HC, Sunahara RK, Seeman P, Niznik HB et al (1991). Cloning of the gene for a human dopamine D4 receptor with high affinity for the antipsychotic clozapine. Nature 350: 610-614.
60. Wang RY (1981). Dopaminergic neurons in the rat ventral tegmental area; I. Identification and characterization. Brain Res Rev 3: 123-140.
61. Werner G, Mountcastle VB (1963). The variability of central neural activity in a sensory system and its implication for the central reflection of sensory events. J Neurophysiol 26: 958-977.
62. White FJ, Wang RY (1983). Differential effects of classical and atypical antipsychotic drugs on A9 and A10 dopamine neurons. Science 221: 1054-1057.
63. Wonnacott S, Kaiser S, Mogg A, Soliakov L, Jones IW (2000). Presynaptic nicotinic receptors modulating dopamine release in the rat striatum. Eur J Pharmacol 393: 51-58.